By designing proteins de novo scientists can more efficiently create novel therapeutics tailored for specific biological ...

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

Advances are occurring in spectroscopy, reducing the challenges of rapid signal saturation and the need for extensive sample prep.

In addition to being faster and less invasive than a traditional tissue biopsy, the blood test is also potentially more accurate.

PRDX6 and GSTP1 identified as promising enzyme targets for neuroblastoma, offering an alternative to retinoic acid differentiation therapy.

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

GEN ranks not only the top 10 publicly traded developed of editing-based therapies, but the top five privately held companies ...

Eli Lilly has agreed to acquire Verve Therapeutics for up to $1.3 billion in a deal designed to bolster the buyer’s cardiovascular treatment pipeline with Verve’s gene editing therapies, led by ...